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Abstract
Background: The cysteine peptidase cathepsin B is important in thyroid physiology by being involved in
prohormone processing initiated in the follicle lumen and completed in endo-lysosomal compartments. However,
cathepsin B has also been localized to the extrafollicular space in thyroid cancer tissue, and is therefore suggested
to promote invasiveness and metastasis in thyroid carcinomas through e.g. extracellular matrix degradation.
Methods: Transport of cathepsin B in normal thyroid epithelial and carcinoma cells was investigated through
immunolocalization of endogenous cathepsin B in combination with probing protease activity. Transport analyses
of cathepsin B-eGFP and its active-site mutant counterpart cathepsin B-C29A-eGFP were used to test whether
intrinsic sequences of a protease influence its trafficking.
Results: Our approach employing activity based probes, which distinguish between active and inactive cysteine
proteases, demonstrated that both eGFP-tagged normal and active-site mutated cathepsin B chimeras reached the
endo-lysosomal compartments of thyroid epithelial cells, thereby ruling out alterations of sorting signals by
mutagenesis of the active-site cysteine. Analysis of chimeric protein trafficking further showed that GFP-tagged
cathepsin B was transported to the expected compartments, i.e. endoplasmic reticulum, Golgi apparatus and endo-
lysosomes of normal and thyroid carcinoma cell lines. However, the active-site mutated cathepsin B chimera was
mostly retained in the endoplasmic reticulum and Golgi of KTC-1 and HTh7 cells. Hence the latter, as the least
polarized of the three carcinoma cell lines analyzed, exhibited severe transport defects in that it retained chimeras
in pre-endolysosomal compartments. Furthermore, secretion of endogenous cathepsin B and of other cysteine
peptidases, which occurs at the apical pole of normal thyroid epithelial cells, was most prominent and occurred in
a non-directed fashion in thyroid carcinoma cells.
Conclusions: Transport of endogenous and eGFP-tagged active and inactive cathepsin B in the cultured thyroid
carcinoma cells reflected the distribution patterns of this protease in thyroid carcinoma tissue. Hence, our studies
showed that sub-cellular localization of proteolysis is a crucial step in regulation of tissue homeostasis. We
conclude that any interference with protease trafficking resulting in altered regulation of proteolytic events leads
to, or is a consequence of the onset and progression of thyroid cancer.
Background
Cathepsin B is a cysteine peptidase belonging to the
papain clan C1A [1,2]. Cysteine cathepsins in general
are homologous with respect to their active-site resi-
dues, i.e. cysteine (Cys) and histidine (His) forming
the catalytic dyad [3]. Cathepsin B is a ubiquitously
expressed member of the family of papain-like cysteine
peptidases, but it is exceptional in exhibiting endo- and
exopeptidase activities [4]. The main proteolytic func-
tion attributed to cathepsin B in physiology is consid-
ered in its catabolic action on proteins reaching endo-
lysosomal compartments [4-6]. Hence, cathepsin B is
considered to predominantly act on its substrates intra-
cellularly, within endocytic compartments. In contrast,
the extracellular occurrence of cysteine peptidases like
cathepsin B is often considered pathological. Severe con-
ditions of excessive cathepsin B-mediated degradation
of extracellular matrix (ECM) components, as it is
observed in osteoarthritis [7], is believed to arise when
cathepsin B is secreted into the extracellular space in a
non-regulated manner. Furthermore, cysteine cathepsins,
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and in particular cathepsin B, are considered to be
involved in malignancies and cancer progression due to
an increase in expression and activity in cancer cells as
well as due to increased secretion from tumor-asso-
ciated cells [8-12].
Because proteases display their functions by an irre-
versible mode of substrate cleavage, it is considered cru-
cial to determine (i) time, (ii) location and (iii) extent of
proteolytic cleavage in order to understand protease
actions in physiology and pathology [1,6,13,14]. Thus,
trafficking of proteases and the tight spatiotemporal reg-
ulation of proteolysis are decisive for normal or diseased
functions of cells or tissues.
In the healthy thyroid gland, cathepsin B bears impor-
tant functions for maintaining the differentiated state of
thyroid epithelial cells in that it contributes to thyroglo-
bulin processing and thyroxine release from the thyroid
follicles [15-18]. This role of cathepsin B in thyroid phy-
siology depends on its polarized secretion at the apical
plasma membrane domain of differentiated normal thyr-
oid epithelial cells [15,16,19]. However, cathepsin B has
also been shown to be localized to the basement mem-
brane of thyroid carcinoma cells in situ, where it was
proposed to facilitate tumor invasiveness and metastasis
through degradation of the extracellular matrix [20].
Recently, we have determined that cathepsin B is the
main active cysteine cathepsin present in the human
thyroid carcinoma cell lines KTC-1, HTh7 and HTh74
cells [21]. This fact, together with the suggested role of
cathepsin B in malignant progression, prompted us to
further analyze trafficking of cathepsin B in KTC-1 cells,
a poorly differentiated papillary thyroid carcinoma cell
line, and in the anaplastic HTh7 and HTh74 thyroid
carcinoma cell lines. KTC-1 cells do not express thyroid
stimulating hormone (TSH) receptors, thyroid peroxi-
dase (TPO) or the sodium iodide symporter (NIS), but
still express thyroglobulin [22]. Thus, these cells are
characterized by both, a maintained and a lost expres-
sion of key components of the physiological thyroid hor-
mone production machinery. In addition, despite a low
expression of thyroglobulin mRNA by HTh74 cells [23],
we and others have shown that this cell line still
expresses functional TSH receptors [21,24].
Here, we expressed cathepsin B and its active-site
mutant counterpart cathepsin B-C29A as chimeric pro-
teins fused to the enhanced green fluorescent protein
(eGFP) as visualization tag. Their transport pathways as
well as their secretory release into the extracellular
space of normal and thyroid carcinoma cell lines were
studied with the help of activity based probes that were
designed to distinguish between active and inactive
cysteine peptidases within the endo-lysosomal compart-
ments of mammalian cells [1,14,25,26]. The results of
our investigations led us to conclude that protease
trafficking is governed by the thyroid cell type investi-
gated, i.e. transport resulting in polarized secretion is
typical for normal, differentiated thyrocytes [1,27]
whereas non-polarized transport pathways and non-
directed secretion were observed in thyroid carcinoma
cells. We therefore propose that cathepsin B transport
to the basolateral plasma membrane domain and its
secretion into the extrafollicular space as observed in
follicular and papillary thyroid carcinoma tissues are fea-
tures of altered trafficking routes in thyroid cancer.
Methods
Cell culture
Fisher rat thyroid (FRT) cells and the human thyroid
carcinoma cell lines KTC-1, HTh7 and HTh74 were
grown at 37°C and 5% CO2 in a moisturized atmo-
sphere. KTC-1 cells were cultured in RPMI-1640 (Bio-
whittaker™, Verviers, Belgium), and HTh7 and HTh74
cells in Eagle´s Minimum Essential Medium (Biowhit-
taker™), all supplemented with 10% fetal calf serum
(FCS; PerBio, Aalst, Belgium). The FRT and KTC-1 cells
analyzed for the secretion of cathepsin B were grown in
Coons F-12 medium (Sigma-Aldrich, Taufkirchen, Ger-
many) containing 2.68 mg/ml sodium bicarbonate and
supplemented with 5% FCS. For KTC-1 cells, a mixture
consisting of 0.166 mg/ml insulin, 2 µg/ml Gly-His-Lys
complex, 0.362 µg/ml hydrocortisone, 0.5 µg/ml trans-
ferrin, 1 µg/ml somatostatin and 100 µU/ml TSH (final
concentrations; all from Sigma-Aldrich) was added. Bar-
rier function and tightness of the epithelial monolayer
of the thyroid carcinoma cell lines grown on permeable
filter supports (pore size 0.4 mm) of Transwell inserts
(Corning Costar Co., Acton, MA, USA) was estimated
by measuring the trans-epithelial electrical resistance
with a Millicell ERS ohmmeter (Millipore, Bedford, MA,
USA). The values were corrected for background resis-
tance measured across filters without cells.
Indirect immunofluorescence
KTC-1, HTh7 and HTh74 cells used for indirect immu-
nofluorescence were cultured on cover slips in 6-well
plates. The cells were fixed with 4% paraformaldehyde
in 200 mM HEPES, pH 7.4, for 30 minutes at room
temperature followed by washing 3 times 5 minutes
with 200 mM HEPES (pH 7.4) and 3 times 5 minutes
with calcium- and magnesium-free PBS (CMF-PBS), i.e.
0.15 M NaCl, 2.7 mM KCl, 1.5 mM NaH2PO4, 8.1 mM
Na2HPO4, pH 7.4. Permeabilization was performed with
0.2% Triton X-100 in CMF-PBS for 5 minutes at room
temperature. For blocking, 3% bovine serum albumin
(BSA; Carl Roth GmbH, Karlsruhe, Germany) in CMF-
PBS was used for 1 hour at 37°C. The cells were incu-
bated with an anti-cathepsin B primary antibody (Neu-
romics, Hiddenhausen, Germany) diluted in 0.1% BSA
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in CMF-PBS overnight at 4°C. After washing with 0.1%
BSA in CMF-PBS, the cells were incubated with Alexa
488-conjugated secondary antibodies (Molecular Probes,
Karlsruhe, Germany) for 1 hour at 37°C together with 5
µM of the nuclear counter-stain DRAQ5™ (Biostatus
Limited, Shepshed, Leicestershire, UK). After washing
with CMF-PBS and de-ionized water, the cover slips
were mounted with embedding medium consisting of
33% glycerol, 14% Mowiol in 200 mM Tris-HCl, pH 8.5
(Hoechst AG, Frankfurt, Germany) on microscopic
slides. When the thyroid carcinoma cell lines were used
for F-actin labelling, they were treated as described
above, but instead of antibody immunolabelling, the
cells were incubated with FITC-phalloidin (3 µM,
Sigma-Aldrich) for 1 hour at 37°C.
Human thyroid tissue was obtained from patients
undergoing thyroid surgery and used in compliance with
the Helsinki Declaration. The tissue was fixed in paraf-
ormaldehyde, embedded in paraffin and sectioned as
described [28]. The tissue sections mounted on micro-
scopic slides were de-paraffinated by washing with xylol
4 times 5 minutes followed by 5 minute-washes with
decreasing concentrations of ethanol (100% to 30%) and
final incubation with freshly prepared sodium borohy-
dride (1%; Carl Roth GmbH) to reduce auto-fluores-
cence, and de-ionized water for 5 minutes each.
Haematoxylin and eosin (0.1%; Sigma-Aldrich) (H&E)
staining was performed in order to examine tissue archi-
tecture. The protocol for indirect immunofluorescence
was performed as described for the cell lines above with
the following modifications. Blocking with 3% BSA was
performed at 4°C overnight, the permeabilization step
was omitted, and the tissue sections were incubated
with the secondary fluorophore-conjugated antibody for
2 hours. In addition, DRAQ5™ was used at a concen-
tration of 20 µM. Three tissue samples from each
pathological condition, i.e. from papillary and follicular
thyroid carcinomas, were prepared as described above
and subjected to analysis.
The immunofluorescence samples were viewed with a
confocal laser scanning microscope (LSM 510 Meta;
Carl Zeiss Jena GmbH, Jena, Germany) and analyzed
with the LSM 510 software, Release 3.2 (Carl Zeiss Jena
GmbH).
Protein precipitation from conditioned media
Conditioned medium was collected from KTC-1 cells
and proteins were precipitated with ice-cold trichloroa-
cetic acid (TCA, 10%). The samples were incubated on
ice for 30 minutes followed by centrifugation at 10 000
g for 10 minutes at 4oC. The supernatant was removed
and centrifugation was repeated at the same speed and
temperature for another 10 minutes. The remaining
supernatant was removed and the pellet was dried in
speed vacuum for 20 minutes and re-suspended in sam-
ple buffer consisting of 10 mM Tris-HCl (pH 7.6), 0.5%
SDS, 25 mM DTT, 10% glycerol and 25 µg/ml bromo-
phenol blue. The sample pH was adjusted using 1.5 M
Tris-HCl at pH 8.8 (Carl Roth GmbH) before loading
onto SDS-gels.
Labelling of active cysteine cathepsins with activity based
probes
HTh74 cells cultured in 6-well plates on cover slips
were washed with pre-warmed PBS, i.e. 0.9% NaCl, 20
mM NaH2PO4, pH 6.8, followed by incubation with Yel-
low-DCG-04 (1 µM) in serum-free growth medium for
30 minutes under standard culture conditions. Washing
with PBS 3 times for 5 minutes was followed by a chase
period of 1 hour with complete cell culture medium and
another set of washes as described above. DRAQ5™ (5
µM) was used as nuclear counter-stain and was added
to the medium for the last 10 minutes of the chase per-
iod. For live-cell imaging, the cover slips with cells were
transferred onto metal slide devices filled with pre-
warmed medium supplemented with 20 mM HEPES to
maintain neutral pH conditions during microscopy, and
analyzed through confocal laser scanning microscopy as
described earlier.
Active cysteine cathepsins in FRT cells were visualized
using a quenched activity based probe (GB117) [25].
Transfected cells were seeded on cover slips in 6-well
plates and cultured until they reached 80-90% conflu-
ence. The cells were washed once with pre-warmed PBS
followed by addition of DMEM without Phenol Red
(Cambrex Bio Science, Wiesbaden, Germany) supple-
mented with 1 μM GB117 and culturing for 3 hours
under normal conditions. The live-cell imaging was per-
formed as described above.
SDS-PAGE and immunoblotting
Whole cell lysates of FRT cells transfected with pEGFP-
N1 plasmid were obtained as follows: the cells were
washed with ice cold PBS, detached with a cell scraper
and collected through centrifugation for 10 minutes at
900 g and 4oC. The cells were resuspended in lysis buf-
fer consisting of 20 mM Na2HPO4, 50 mM NaCl, 0.2%
Triton X-100, pH 7.4, and supplemented with a pro-
tease-inhibitor-mix, i.e. 0.1 mM E64, 0.01 mM Pepstatin,
2 ng/ml Aprotinin, 0.02 M EDTA, followed by incuba-
tion for 30 minutes at 4oC on a end-over-end rotor.
The supernatants were cleared through centrifugation
for 15 minutes at 15 000 g and 4oC.
The Bradford assay [29] was used in order to deter-
mine the protein concentration of the samples. The pro-
teins and a cathepsin B standard from bovine spleen
(Sigma-Aldrich) were separated through SDS-PAGE on
12.5% polyacrylamide gels along with a PageRuler pre-
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stained protein ladder (Fermentas, St Leon-Rot,
Germany) or a See Blue pre-stained standard (Novex,
Frankfurt/Main, Germany), and transferred to a nitrocel-
lulose membrane by semi-dry blotting. Unspecific binding
sites were blocked with 5% non-fat milk in PBS contain-
ing 68 mM NaCl, 63.2 mM Na2HPO4, 11.7 mM
NaH2PO4, pH 7.2, supplemented with 0.3% Tween (PBS-
T) overnight at 4°C. Incubation with goat anti-mouse
cathepsin B (Neuromics), rabbit anti-rat cathepsin B
(Upstate Biotechnology, Lake Placid, NY, USA), rabbit
anti-human cathepsin L (RD Laboratorien GmbH, Dies-
sen, Germany) or rabbit anti-human b-tubulin (Abcam,
Cambridge, UK) primary antibodies diluted in PBS-T was
for 2 hours at room temperature followed by incubation
with horseradish peroxidase-conjugated secondary antibo-
dies (Southern Biotech, Birmingham, Al, USA) for 1 hour
at room temperature. Incubation with the peroxidase
substrate (ThermoScientific, Bonn, Germany) was fol-
lowed by visualization through enhanced chemi-lumines-
cence on XPosure films (ThermoScientific).
Construction of the active site mutant cathepsin B-C29A-
eGFP
Cathepsin B cDNA was derived from FRTL-5 cells, a
Fisher rat thyroid cell line, as described previously [27].
For site directed mutagenesis and generation of pCathB-
C29A-eGFP, the CathB 49-1068 forward primer [27]
was combined with a newly designed primer CB-
Cys29Ala reverse, 5’ – AGA GCC ACA GGA GCC
CTG GT – 3’, giving rise to the amplification of the
first 300 base pairs (bps) of the cathepsin B cDNA. The
CB-Cys29Ala reverse primer was constructed such that
a codon was changed from TGT to GCT, causing the
exchange of cysteine to alanine at amino-acid position
29 of rat cathepsin B. Next, a second PCR reaction was
performed using CB-Cys29Ala forward, 5’ – GGC TCC
TGT GGC TCT GCT TGG GCA TTT G – 3’, in com-
bination with the CathB 49-1068 reverse primer [27],
giving rise to the last approximately 700 bps from the
3’-end of the Ctsb gene. Thereby, two mutations were
caused, namely the already mentioned exchange from
TGT to GCT (see above) and a ‘silent’ mutation (GGG
to GGC), which would not alter the amino acid compo-
sition upon translation, but resulted in the omission of a
restriction site for EcoO109I. Thus, the silent mutation
allowed for better analysis of cloning success. In addi-
tion, the sequences of the primers were designed such
that an EcoRI as well as a BamHI cleavage site were
inserted at the 5’- and the 3’-ends of the cDNA, respec-
tively, to allow for the insertion of the complete coding
sequence of cathepsin B into the pEGFP-N1 vector after
fusion PCR was performed as follows and as previously
described [27]. The PCR products were separated
on 1% agarose gels and the DNA was stained with
ethidiumbromide. The 300-bps- and 700-bps-Ctsb
fragments were cut out, purified from the gel and used
as templates for a fusion PCR reaction. Here, the CathB
49-1068 primer pair [27] was used in order to amplify
full-length cathepsin B cDNA bearing the above men-
tioned sequence mutations. This step was repeated and
gained the cathepsin B-C29A-fragment with the correct
size of 1019 bps, which was excised from the gel, puri-
fied and used for subsequent digestion with EcoRI and
BamHI restriction enzymes and insertion into pEGFP-
N1 as described [27]. The resulting plasmid is schemati-
cally illustrated in Figure 1A. Competent E.coli JM109
cells were transformed with re-ligated vectors in order
to amplify the plasmids. Bacteria were grown using
kanamycin as selection antibiotic, and resistant clones
were checked for their plasmid content by colony-PCR
using CathB 49-1068 forward and reverse primers. Plas-
mid-DNA was prepared from overnight cultures. Both
plasmids were sent for sequencing to verify correct
DNA sequences (see Figure 1B).
Transfection of thyroid cells
Transfection of FRT, KTC-1, HTh7 and HTh74 cells
with pEGFP-N1, pCathB-eGFP or pCathB-C29A-eGFP
was carried out using jetPEIMan (Qbiogene, Heidelberg,
Germany), a mannose-conjugated linear polyethylene
imine, which is able to compact DNA into positively
charged particles followed by binding of the jetPEI-
Man-DNA complexes to cell surface mannose-specific
receptors and internalization through endocytosis. FRT
and human thyroid carcinoma cells were seeded in 6-
well plates on cover slips and transfected at 50-60% con-
fluence. Transfection was performed according to the
manufacturers instructions and by mixing jetPEI-Man
and plasmid DNA at N/P ratios of 5 based on N-resi-
dues of the transfection reagent (7.5 mM) as compared
to anionic phosphate of the plasmid DNA (3 nM/μg).
The transfected cells were cultured for 24 hours under
normal cell culture conditions. On the following day,
transfection medium was exchanged for normal med-
ium. The transfected cells were either analyzed directly
through live-cell imaging with a confocal laser scanning
microscope as described above or, in case of pCathB-
C29A-eGFP transfected FRT cells, they were subjected
to antibiotic selection with G418 (Merck KGaA, Darm-
stadt, Germany).
Results
Localization of cathepsin B in human thyroid tissue
Human tissue obtained from patients affected by follicu-
lar thyroid carcinoma (FTC) or papillary thyroid carci-
noma (PTC) was analyzed in order to determine the
general tissue architecture and the localization of endo-
genous cathepsin B. Haematoxylin and eosin-stained
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pCathB-eGFP GTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCT





































TATATCA ACA A ACAGA ATACA ACATGGCAGGCTGGACGCA ACTTCTACA ATGTTGACATA
AGCTATCTGAAGAAGCTGTGTGGAACTGTCCTGGGTGGACCCAAGCTGCCGGAAAGGGTT
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TACA ATTCTCATATAGGCTGCTTACCCTACACCATCCCTCCCTGTGA ACACCATGTCA AT
GGCTCCCGTCCCCCATGCACTGGAGAAGGAGATACTCCCAAGTGCAACAAGATGTGTGAG
GCTGGCTACTCCACATCCTACA AGGA AGATA AGCACTATGGGTACACTTCCTACAGTGTG
TCTGACAGCGAGAAGGAGATCATGGCGGAAATCTACAAAAATGGCCCAGTGGAGGGTGCT
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Figure 1 Schematic depiction and sequence of pCathB-C29A-eGFP coding for inactive cathepsin B-eGFP chimeras. Schematic
representation (A) and nucleotide sequence (B) of the mammalian expression vector pCathB-C29A-eGFP that codes for eGFP-tagged cathepsin B
containing a cysteine-to-alanine substitution in its active site (yellow) which was introduced by site-directed mutagenesis of the cathepsin B
coding sequence inserted into pEGFP-N1 by using EcoR1 and BamH1 restriction sites. The plasmid bears a CMV promotor (dark grey) as well as
an origin of replication (pUC ori, light gray). The eGFP coding sequence (green) is located down-stream of the cathepsin B encoding DNA minus
the nucleotides encoding the C-terminal pro-peptide extension of the enzyme. In the resulting chimeric protein, cathepsin B will be fused to
eGFP by a 6-amino-acids linker peptide (light red). The sequences of pCathB-eGFP [27] and the active-site mutant pCathB-C29A-eGFP were
aligned by means of ClustalW (version 1.82) multi alignment tool. The sequences are identical, except for the point mutations inserted through
site-directed mutagenesis, and resulting in a GGG to GGC ‘silent’ mutation (red), as well as a TGT to GCT codon exchange (orange), causing a
cysteine to alanine exchange within the active-site of cathepsin B.
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PTC tissue displayed normal thyroid histomorphology
with variably sized follicles and colloid-containing
lumina that were enclosed by a monolayer of epithelial
cells (Figure 2A, follicle lumina denoted with asterisks).
In addition, papillary stalks and disorganized neoplastic
areas lacking clear follicular structures were abundantly
detected in PTC-derived tissue (Figure 2A, dashed
arrows). Heterogenous histomorphology was also detect-
able in haematoxylin and eosin-stained FTC-derived tis-
sue that demonstrated both intact follicles (Figure 2D,
follicle lumina denoted with asterisks), microfollicles
and disorganized neoplastic areas (Figure 2D, dashed
arrows). Cathepsin B was shown by immunostaining to
be localized within vesicular structures located close to
the apical plasma membrane in the non-altered areas of
thyroid carcinoma tissue (Figure 2B and E, arrows). In
the areas with altered morphology of the same tissue,
however, cathepsin B-positive vesicles were detected
only occasionally at the plasma membrane and appeared
distributed throughout the cytosol of thyroid follicle
cells (Figure 2C and F, arrowheads) that were further
characterized by abnormal nuclear morphology and by
less polarized states than thyroid cells in normal tissue
areas (Figure 2C and F, open arrowheads). In addition,
cathepsin B-containing vesicles were localized to the
basolateral poles as highlighted by immunostaining of
the basal plasma membrane domains of neoplastic
cells in PTC (Figure 2C, arrowheads) and of the lateral
plasma membrane domains in FTC tissue (Figure 2F,
arrowheads), indicating non-directed cathepsin B secre-
tion into the extrafollicular space.
This change in cathepsin B distribution from a promi-
nent apical localization in normal to a basolateral locali-
zation in neoplastic areas is therefore not a feature of
PTC alone [20], but also observed in FTC. This notion
made us to hypothesize that protease trafficking is dra-
matically altered in thyroid carcinoma, which led us to












































Figure 2 Tissue architecture and distribution of cathepsin B in thyroid carcinoma in situ. Micrographs of haematoxylin and eosin stained
tissue of thyroid tissue derived from patients with papillary (A) and follicular (D) thyroid carcinoma (PTC and FTC, respectively) was inspected by
brightfield microscopy. PTC tissue displayed areas with intact follicle structures (A) as well as areas with a disorganized tissue structure (A, dashed
arrows). In addition, PTC tissue displayed fibrovascular cores (A). FTC tissue also displayed areas with intact follicle structures as well as areas with
a disorganized tissue structure (D, dashed arrows). Merged (B, C, E, F), single channel fluorescence and corresponding phase contrast
micrographs (left panels) taken with the confocal laser scanning microscope of thyroid tissue from patients with PTC or FTC showing the
endogenous distribution of cathepsin B (green, left panels, top). The nuclei were visualized through DRAQ5™ counter-staining (blue, left panels,
middle). Note that cathepsin B was localized to vesicles close to the apical plasma membrane (arrows) in non-neoplastic areas of thyroid
carcinoma tissue (B and E, respectively). Cathepsin B distribution was different in the disorganized, neoplastic areas of thyroid carcinoma tissue (C
and F). The protease was immunolocalized to vesicles scattered in the cell periphery along the basal and lateral plasma membrane domains as
well as scattered throughout the cytosol (C and F, arrowheads). Nuclei of cells in neoplastic areas displayed an abnormal morphology (C and F,
open arrowheads). Follicle lumina are denoted by asterisks. Scale bars represent 50 µm in A and D, and 20 µm in B, C, E, and F.
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in different thyroid carcinoma cell lines that are known
to exhibit at least some features of differentiated thyro-
cytes although being transformed and representative of
papillary and anaplastic thyroid carcinoma cells. Traf-
ficking of cathepsin B in normal thyroid epithelial cells
that are fully differentiated and exhibit a polarized phe-
notype, i.e. FRT cells, was studied for comparison.
KTC-1, HTh7 and HTh74 as model cell lines to study
cathepsin B trafficking in thyroid carcinoma
Thyroid carcinoma cells of variable aggressiveness differ
in the degree of differentiation and polarization [30,31].
In this study, we have used the papillary thyroid carci-
noma cell line KTC-1 as well as the anaplastic thyroid
carcinoma cell lines HTh7 and HTh74 [22,23].
KTC-1 and HTh74 cells displayed prominent stress
fibers running throughout the cytosol when F-actin was
stained with FITC-phalloidin (Figure 3A and C, arrows),
whereas HTh7 cells have lost the ability to tightly
adhere to the substratum and lacked actin stress fibers
(Figure 3B). Thus, KTC-1 and HTh74 cells in particular
were polarized and should therefore, in principle, have
the ability to establish and maintain an epithelial
monolayer, which was analyzed by determination of the
trans-epithelial electrical resistance (TER) as a measure
of monolayer tightness [32]. KTC-1 cells indeed formed
a confluent monolayer but displayed a low TER of 500
± 100 Ω x cm2. In contrast, HTh7 and HTh74 cells
were able to hyper-proliferate in culture, thereby form-
ing mono- and multi-layers which were not tight since
no TER was measurable. Therefore, KTC-1 cells must
be considered to maintain contact-inhibition to some
extent, which was clearly lost in HTh74 cells despite
their ability to adhere to the substratum in a polarized
fashion. In addition, adherens and tight junction pro-
teins such as E-cadherin, claudin-1 and occludin have
been detected at the lateral plasma membrane domains
of KTC-1 cells (our own unpublished observations; KBr,
Laura Panavaite, ST, all Bremen), thus further support-
ing maintenance of epithelial polarity to some extent in
this cell line.
Because of the morphological and functional appear-
ance of KTC-1 cells as well as due to the lack of con-
tact-inhibition in hyper-proliferative HTh7 and HTh74
cells, we considered these cell lines suitable to represent
distinct stages in epithelial-to-mesenchymal transition
KTC-1F-Actin HTh7 HTh74F-Actin F-Actin
A B C
Monolayer
2TER 500 ± 100  x cm
Monolayer
2TER 0  x cm
Multilayer
2TER 0  x cm
Figure 3 Thyroid carcinoma cell lines as model systems. Fluorescence micrographs of the papillary thyroid carcinoma cell line KTC-1 (A) and
the anaplastic thyroid carcinoma cell lines HTh7 and HTh74 (B and C, respectively) taken with the confocal laser scanning microscope after
fixation and phalloidin staining of the F-actin cytoskeleton. KTC-1 and HTh74 cells displayed stress fibers throughout the cytosol (A and C,
arrows) as well as cortical F-actin underneath the plasma membranes. In HTh7 cells stress fibers were largely lacking (B) but cortical F-actin was
displayed (B, arrowheads). KTC-1 cells grew in a monolayer fashion and established only a weak barrier as estimated by determination of the
trans-epithelial electrical resistance (TER), whereas HTh7 cells formed non-tight monolayers and HTh74 cells grew in multilayers. Scale bars
represent 20 µm.
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with HTh7 cells being the most progressed toward the
mesenchymal phenotype, but HTh74 cells being the
most transformed with respect to proliferation and loss
of contact inhibition.
Cathepsin B is secreted from KTC-1 cells
We have previously shown that cathepsin B is one of
the main if not the major cysteine peptidase active in
KTC-1, HTh7 or HTh74 cells, and that its predominant
expression pattern is vesicular in these thyroid carci-
noma cell lines [21]. In this study, we were interested in
the investigation of the 3-dimensional distribution of
cathepsin B-containing vesicles through optical section-
ing by means of confocal laser scanning microscopy in
order to approach determination of the transport path-
ways of the endogenous protease before analyzing traf-
ficking of GFP-tagged chimeras of active and inactive
cathepsin B.
Optical sections (xy) were taken at different focal
planes of cultured KTC-1 cells in z-direction, i.e. per-
pendicular to the cellular poles attaching to the substra-
tum. Cathepsin B was detected by immunofluorescence
staining within reticular structures and vesicles gather-
ing in the peri-nuclear region (Figure 4A1-A3, arrows)
and in a dotted pattern (Figure 4A1-A3, B, D, arrow-
heads). When the sections of an entire z-stack were
compiled and reconstructed in xz, i.e. displayed as side
view as schematically indicated in 4C, it became evident
that cathepsin B-positive structures were localized in a
dotted fashion in close proximity to the cell periphery
(Figure 4B and D, arrowheads). This close proximity to
the cell surfaces is most probably an indication of cathe-
psin B being released either towards the apical pole
(representative of into the follicle lumen) or towards the
basal side (representative of towards the extrafollicular
space) and its subsequent re-association with the plasma
membrane of KTC-1 cells.
Therefore, we next analyzed the media conditioned by
KTC-1 cell cultures for possible occurrence of secreted
forms of cathepsin B. In fact, KTC-1 cells were able to
secrete mature, proteolytically active cathepsin B,
because both, the single chain (SC) and the heavy chain
(HC) of the two-chain form of cathepsin B were detect-
able in the conditioned media (Figure 4E). The levels of
both, single and heavy chain cathepsin B increased stea-
dily over time, indicating constant secretion of mature
forms of cathepsin B from KTC-1 cells.
Visualization of active cysteine cathepsins in HTh74 cells
In order to visualize active cysteine cathepsins in thyroid
carcinoma cell lines, we used the activity based probe
DCG-04 that binds covalently to active cysteine pepti-
dases in a 1:1 ratio [26]. In HTh74 cells, proteolytically
active cysteine peptidases were shown to be distributed
throughout the cells in vesicles of various sizes (Figure
5A1-A3 and B, arrows). In addition, active cysteine pep-
tidases were labeled with DCG-04 in differently sized
aggregates that were localized in the extracellular space
at both poles in between cells throughout the multi-
layered cultures (Figure 5D, arrowheads). In particular,
large DCG-04 positive cysteine peptidase-containing
aggregates were found abundantly in association with
the surfaces of HTh74 cells of the different layers
(Figure 5B and D, arrowheads, schematically depicted in
C). It was taken special care to wash the DCG-04 treated
cells thoroughly before microscopy to avoid that aggre-
gates would increase in size artificially during mounting
for live-cell microscopy. Because the aggregates were visi-
ble in all focal planes above, in between, and below the
multi-layers of HTh74 cultures (Figure 5D, green signals)
and since they were not co-stained with DRAQ5™, we
considered these structures as resulting from secretion of
active cysteine peptidases rather than being derived from
dead cells.
Construction of a cathepsin B-C29A-eGFP coding vector
For in vivo analyses of cathepsin B-trafficking, vectors
coding for different eGFP chimeras were used. As a con-
trol for normal trafficking of cathepsin B, the cDNA for
cathepsin B from FRTL-5 cells, was cloned into the
pEGFP-N1 vector [27]. To test whether the proteolytic
activity of cathepsin B would affect its transport to dis-
tinct compartments, i.e. whether intrinsic sorting signals
of the active enzyme would be a prerequisite of proper
trafficking, the cDNA sequence coding for rat cathepsin
B was altered by site-directed mutagenesis. The modi-
fied cDNA was cloned into pEGFP-N1, thereby con-
structing a vector coding for an inactive cathepsin
B-C29A-eGFP chimera (Figure 1A).
The sequences of the inserted DNA for pCathB-eGFP
and pCathB-C29A-eGFP revealed identical nucleotide
sequences coding for cathepsin B, except the specifically
inserted mutations, i.e. the codon exchange at position
421-423 for the cysteine to alanine exchange (Figure 1B,
sequence 1) as well as a restriction site omission at posi-
tion 406-408. The so-called C-terminal extension of
cathepsin B, normally at amino acid positions 334-339,
which is not needed for protease function [33] was lack-
ing in both constructs, because both were linked to the
eGFP portion by a 6-amino-acid spacer peptide instead.
Expression of eGFP-tagged active and inactive cathepsin
B in rat thyroid cells
FRT cells, a thyroid epithelial cell line derived from
Fisher rats, form monolayers with tight and adhesive
junctions separating apical and basolateral plasma mem-
brane domains from each other. Therefore, they are an
excellent model system to study the morphological
Tedelind et al. Thyroid Research 2011, 4(Suppl 1):S2
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properties of thyrocytes, which are highly polarized in
situ[27,34]. FRT cells were transfected with pCathB-
eGFP and pCathB-C29A-eGFP by means of jetPEI-Man.
The expression of cathepsin B-eGFP as well as of the
active-site mutant cathepsin B-C29A-eGFP showed
prominent signals of the chimeric proteins within
numerous vesicles that were reminiscent of endo-lysoso-
mal compartments because of their accumulation within
the peri-nuclear regions of FRT cells (Figure 6A and B,
arrows). Importantly, the cathepsin B-eGFP chimeric
protein has been shown not to be over-expressed in





























Figure 4 Secretion of endogenous cathepsin B from KTC-1 cells. Single channel fluorescence micrographs of cathepsin B localization in KTC-
1 cells as detected by immunolabelling and confocal laser scanning microscopy (A, B, D). Three-dimensional distribution of cathepsin B
representative signals is sketched in C. Single optical sections taken in xy were obtained in different focal planes (A1-A3, cf. lines in C) and
compiled in a zero-projection as an extended focus (B) as well as in xz-direction as a side view (D). Cathepsin B displayed a reticular and
vesicular staining pattern throughout the cell, and it appeared extracellularly in a dotted fashion due to its re-association with the plasma
membrane (A-D, arrowheads). Note that cathepsin B secretion was non-directional. The dashed line in B denotes the cell circumference. Scale
bars represent 10 µm. (E) TCA-precipitated and SDS-PAGE separated proteins from conditioned media of KTC-1 cells were immunoblotted with
anti-cathepsin B antibodies. Note the presence of mature forms of cathepsin B, i.e. single chain (SC) and heavy chain (HC) cathepsin B in
conditioned media and their increasing amounts with time. Immunoblotting of beta-tubulin in the corresponding whole cell lysates were used
as loading controls.
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cells, eGFP-tagged cathepsin B and its active-site mutant
were destined to endo-lysosomes, thereby ruling out that
the active site mutation affected the structure and folding
of cathepsin B in such a way that it would induce major
alterations in its cellular transport pathways.
However, by eGFP-tagging alone it could not be deter-
mined whether identical vesicles contained both, the
active protease cathepsin B (or any other active cysteine
cathepsin) and its inactive counterpart cathepsin B-
C29A-eGFP. Therefore and in order to directly visualize
active cysteine cathepsins versus inactive cathepsin B,
pCathB-C29A-eGFP-transfected FRT cells were addi-
tionally labeled with activity based probes as reporters
of proteolytic activity of cysteine peptidases. In this case
we used GB117, a quenched Activity Based Probe
(qABP) that reacts primarily with the active forms of
cysteine cathepsins B, L, and S [25]. The big advantage
of using a qABP is that it contains a fluorescence
donor- and a quencher group keeping it non-fluorescent
before binding to and reacting with an active cysteine
peptidase [6,25]. Upon covalent attachment of the qABP
by reacting with the active-site residues of an active pro-
tease molecule, the quencher is released and fluores-
cence is exhibited. Hence, GB117 provides a tool to
analyze whether inactive cathepsin B-C29A-eGFP is
transported to vesicles that also contain active proteases,
or, instead, whether the active site mutant counter-part
of cathepsin B displayed sorting signals that would
enable transport to a different vesicle population which
















Figure 5 Visualization of active cysteine cathepsins in HTh74 cell cultures. Merged fluorescence micrographs of HTh74 cells growing in
multilayers as detected after incubation with the fluorophore-conjugated activity based probe DCG-04 (green signals), counter-staining of
nuclear DNA with DRAQ5™ (blue signals), and confocal laser scanning microscopy (A, B, D). The activity based probe DCG-04 binds to the active
site of mature cysteine peptidases in a 1:1 ratio and visualizes proteolytically active cysteine proteases, only. Three-dimensional distribution of
cysteine peptidase representative signals is sketched in C. Single optical sections taken in xy were obtained in different focal planes (A1-A3, cf.
lines in C) and compiled in a zero-projection as an extended focus (B) as well as in xz-direction as a side view (D). Active cysteine peptidases
were localized to variably sized vesicles throughout the cell (arrows). In addition, active cysteine peptidases were secreted from HTh74 cells and
associated in aggregates with the plasma membrane (arrowheads). Note that active cysteine peptidases were secreted in a non-directional
fashion at all poles of HTh74 thyroid carcinoma cells (D, arrowheads). Scale bars represent 10 µm.
Tedelind et al. Thyroid Research 2011, 4(Suppl 1):S2
http://www.thyroidresearchjournal.com/content/4/S1/S2














































Cath BCath LCath Sâ-TubulinC
N
N
Figure 6 Expression of cathepsin B-eGFP and cathepsin B-C29A-eGFP chimeras in normal thyroid epithelial cells. Single channel
fluorescence (A and B, left panels in D), merged (D) and corresponding phase contrast micrographs (insets in A and B, left panel, bottom, in D)
taken with the confocal laser scanning microscope of FRT cells after transfection with plasmids coding for eGFP-tagged active (A) and inactive
cathepsin B (B and D) as indicated. The expression pattern of both chimeric proteins was vesicular in FRT cells (arrows in A and B, green signals
in D). The endogenous levels of mature cathepsins B, L and S (SC – single chain, HC – heavy chain) were estimated through immunoblotting
and densitometry analysis and the cathepsins B:L:S ratio was shown to be 7:3:0 (C). The cathepsin levels were normalized against b-tubulin (C,
arrowhead) that was used as a control for equal loading. The quenched activity based probe GB117 became fluorescent upon reaction with
active cysteine peptidases and exhibited a vesicular staining indicative of active cysteine cathepsins in endo-lysosomal compartments (red signals
in D). Note that the inactive cathepsin B-C29A-eGFP protein was localized within the same (yellow signals) or different vesicles (green signals) of
normal rat thyroid epithelial cells (D), ruling out the existence of sorting signals intrinsic in cathepsin B’s primary structure. N denotes nuclei.
Scale bars represent 20 µm.
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However, since GB117 has been shown to have a
relative selectivity for cathepsin L over cathepsins B
and S [25], we analyzed the amounts of these three
cathepsins in whole cell fractions of FRT cells trans-
fected with pEGFP-N1 vectors, i.e. lacking the cDNA
coding for active or inactive cathepsin B, by immuno-
blotting. The amounts of mature cathepsin B (single
chain plus heavy chain normalized to ß-tubulin)
exceeded those of cathepsin L by more than 2-fold
while cathepsin S was not detectable at all (Figure 6C).
We can therefore conclude that GB117 evoked signals
in FRT cells would derive primarily from its interaction
with cathepsin B.
Next, cathepsin B-C29A-eGFP expressing FRT cells
were analyzed by live-cell imaging after incubation with
GB117 for 3 hours at normal cell culture conditions.
The labelling of active cysteine peptidases with GB117
in FRT cells expressing inactive cathepsin B-eGFP chi-
meras resulted in a vesicular staining pattern, indicative
for the presence of active cysteine proteases in endo-lyo-
sosomal compartments (Figure 6D, red signals). Further-
more, the GB117-labeled molecules co-localized with
cathepsin B-C29A-eGFP chimeras within these vesicular
structures, as was obvious from the yellow signals
resulting from overlapping of red and green signals
(Figure 6D, yellow signals). However, some vesicles were
positive for cathepsin B-C29A-eGFP but lacked the sig-
nal for GB117 (Figure 6D, green signals). Thus, eGFP-
tagging of the inactive cathepsin B mutant form as well
as qABP-tagging of active cysteine proteases resulted in
the notion that most endosomes and lysosomes of nor-
mal, polarized thyroid epithelial cells contained mixtures
of active and inactive cysteine proteases thereby ruling
out that active and inactive cathepsin B were sorted into
distinct vesicle populations. These results indicated that
sorting signals are unlikely to exist in the vicinity of the
active site cleft of cathepsin B.
Localization of active and inactive cathepsin B fused to
eGFP in thyroid carcinoma cell lines
Next, we were interested to determine whether cathe-
psin B trafficking is altered in thyroid carcinoma cells in
comparison to normal thyroid epithelial cells. The active
cathepsin B-eGFP chimeric protein was localized to
vesicular structures in KTC-1 and HTh74 cells (Figure
7A and C), i.e. in a similar distribution pattern as that
observed for endogenous cathepsin B. Thus, cathepsin
B-eGFP is likely following the same transport pathway
as endogenous cathepsin B. HTh7 cells, on the other
hand, displayed an accumulation of CB-eGFP in the
endoplasmic reticulum (ER) and was retained even more
prominent in the Golgi apparatus (Figure 7B). This loca-
lization pointed to a transport defect of this thyroid car-
cinoma cell line, because the cathepsin B pattern
observed by expression of the GFP-tagged protease was
reminiscent to the predominant reticular staining pat-
tern with only few vesicular structures that were immu-
nolabeled in KTC-1 cells with cathepsin B-specific
antibodies (see, Figure 4).
When the inactive cathepsin B-C29A-eGFP chimeras
were expressed in KTC-1 and HTh7 cells, the green
fluorescence was abundant in the endoplasmic reticulum
(Figure 7D and E, arrowheads) but mostly absent from
endo-lysosomes. In contrast, HTh74 cells expressing the
inactive cathepsin B-C29A-eGFP chimeric protein still
displayed a vesicular staining pattern resembling the
peri-nuclear pattern of endo-lysosomal compartments
(Figure 7F).
Discussion
Cathepsin B processes thyroglobulin under physiological
conditions in the extracellular follicle lumen as well as
in endo-lysosomal compartments which is followed by
the release of thyroid hormones from the thyroid gland
[15-17]. Hence, transport of cathepsin B to the apical
plasma membrane domain of normal thyroid epithelial
cells is a prerequisite for its TSH-stimulated secretion
into the follicle lumen in order to maintain thyroid
homeostasis [19]. In pathological conditions, however,
such as papillary thyroid carcinoma, cathepsin B has
been localized to the basement membrane [20]. Here we
provide evidence that such re-routing of cathepsin B
transport from apical-to-basolateral poles is a hallmark
also of neoplastic cells in FTC (see Figure 2). Therefore,
we propose that cathepsin B transport towards basal
poles is characteristic for cells in both, papillary and fol-
licular thyroid carcinoma, whereas an apical-directed
transport that is characteristic for thyrocytes of normal
thyroid tissue, is also still displayed in cells of PTC and
FTC-derived tissue areas with intact follicle structures.
This notion motivated us to analyze the pathways
resulting in altered cathepsin B trafficking and leading
to its secretion into the extrafollicular space, which
most probably enhances the invasive potential of thyroid
carcinoma cells due to cathepsin B’s ability to degrade
ECM components [1,10-12,35,36].
The data achieved by 3-dimensional immunolocaliza-
tion of endogenous cathepsin B and experiments
employing activity based probes indicated that the thyr-
oid carcinoma cell lines investigated in this study were
characterized by cathepsin B trafficking that is destined
to endo-lysosomes and, in addition, that cathepsin B is
secreted into the extracellular space in a proteolytically
active form (see Figures 4 and 5). Moreover, secretion
of cathepsin B and related cysteine peptidases from
KTC-1 and HTh74 cells was non-directed. We conclude
that active cysteine peptidases are likely to reach extra-
follicular locations in thyroid carcinoma tissue.
Tedelind et al. Thyroid Research 2011, 4(Suppl 1):S2
http://www.thyroidresearchjournal.com/content/4/S1/S2
Page 12 of 16
From the trafficking studies with GFP-tagged chi-
meras, it can be deduced that the active site mutant of
cathepsin B, which is transport competent and reaches
endo-lysosomes of FRT and HTh74 cells, is retained in
the endoplasmic reticulum of KTC-1 and HTh7 cells
(see Figures 6 and 7). Furthermore, eGFP-tagged wild
type cathepsin B was retained in the Golgi of HTh7
cells. Hence, trafficking of cathepsin B is largely inde-
pendent of signals intrinsic in the primary structure of
the protease, rather transport pathways differ in the
thyroid cell lines tested with trafficking defects being
more prominent in the thyroid carcinoma cell lines
KTC-1 and HTh7, while HTh74 cells remained trans-
port competent and sorted cathepsin B into endo-lyso-
somes. This is likely to be the prerequisite for the
massive secretion of cysteine peptidases like cathepsin B
into the extracellular space of HTh74 cell cultures (see
Figure 5) and it is likely to explain, why this cell line in
particular has lost its contact inhibition and acquired an
invasive phenotype.
Protease transport in mammalian cells
The molecular mechanisms underlying protease traffick-
ing to their points-of-action have been studied in a vari-
ety of tissues and cell types [6,27,37-39]. However, the
transport of proteases in mammalian cells is still not
fully understood up until today [1]. Cysteine cathepsins,
i.e. endo-lysosomal proteases that may also act extracel-
lularly, are synthesized as inactive pre-pro-enzymes at
the rough ER (rER). There, the signal peptide is cleaved-
off co-translationally. In the oxidizing milieu of the ER
lumen, disulfide bridges are formed with the help of
protein disulfide isomerase (PDI), an ER-resident
enzyme, assisting in the correct folding of the proteins.
Further, N-glycosylation of the synthesized proteases


























Figure 7 Expression of cathepsin B-eGFP and cathepsin B-C29A-eGFP chimeras in thyroid carcinoma cells. Single channel fluorescence
(A-F) and corresponding phase contrast micrographs (insets) taken with the confocal laser scanning microscope of KTC-1 (A and D), HTh7 (B
and E) and HTh74 cells (C and F) after transfection with plasmids coding for eGFP-tagged active (A-C) and inactive cathepsin B (D-F) as
indicated. The localization of the eGFP-tagged cathepsin B was vesicular in KTC-1 and HTh74 cells (A and C, arrows), whereas it was retained in
the Golgi of HTh7 cells (B). In contrast, the eGFP-tagged active site mutant counter-part of cathepin B was localized within reticular structures,
the Golgi apparatus and a few vesicles (arrows) of KTC-1 (D) and HTh7 cells (E), while it was mainly localized to vesicles of HTh74 cells (F),
indicating that the inactive mutant form of cathepsin B is transport-competent in principle. N denotes nuclei. Scale bars represent 10 µm.
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Thr-Y motif (amino-acids given in three-letter code,
with ‘X’ indicating any amino-acid, and ‘Y’ indicating
any amino-acid except proline) by means of oligosac-
charyl transferase. The pro-forms of cysteine cathepsins
are further transported to the Golgi apparatus, where
the zymogenes are modified in terms of N-linked oligo-
saccharide processing resulting in the addition of man-
nose-6-phosphate residues by a phosphotransferase and
a phosphodiesterase. The mannose-6-phosphate tags are
recognized in the trans-Golgi network (TGN) by highly
specific mannose-6-phosphate receptors (M6P-R), which
sort the pro-forms of cysteine proteases directly to the
endo-lysosomal compartments [40]. However, some
M6P-tagged proteins like for instance thyroglobulin or
the aspartic lysosomal protease cathepsin D, escape
endo-lysosomal targeting in thyroid epithelial cells and
become secreted instead [41,42].
These results are similar to observations made in
lysosomal storage diseases, such as I-cell disease, where
it was shown that transport pathways of lysosomal
enzymes may differ tremendously with respect to the
cell type. For instance, I-cell disease patients lack an
enzyme responsible for the addition of the M6P-tag, i.
e. phosphotransferase, thus the lysosomal enzymes are
not transported to the endo-lysosomal compartments,
but become secreted [39]. The mis-routing of lysoso-
mal enzymes was also examined in fibroblasts isolated
from mice deficient in M6P-receptors and displaying
an I-cell disease-like phenotype [43]. Interestingly, iso-
lated hepatocytes from the same mice exhibited the
complete set of enzymes within their endo-lysosomal
compartments [44] highlighting that alternative path-
ways of endo-lysosomal targeting exist. Furthermore, it
has been shown that cathepsin B can reach peripherally
located vesicles in cancer cells by a pathway that is
independent of M6P and most probably driven by sort-
ing signals located within the pro-peptide region of the
enzyme [45].
Hence, even though compelling evidence for alterna-
tive trafficking mechanisms has been published, the
underlying sorting signals or alternative transport routes
were not fully elucidated until today (for review see
[46]). An excellent model system for the study of trans-
port differences are cells which are characterized by dis-
tinct plasma membrane domains thus polarized into a
basolateral and an apical plasma membrane domain. In
order to elucidate the mechanisms that trigger apically
or basolaterally-directed transport, Madin-Darby canine
kidney cells (MDCK) or the thyroid epithelial cell line
FRT have been intensively studied. Interestingly, FRT
cells transport plasma membrane proteins to opposite
cell poles as MDCK cells, even though both cell lines
are polarized and display apparently morphological fea-
tures of differentiated epithelial cells [27,34,47,48].
Interestingly, the precise mechanisms that explain why
e.g. transmembrane proteins are inserted into either the
basolateral or the apical plasma membrane domain of
MDCK or FRT cells, respectively, remain elusive. How-
ever, because thyrocytes are able to perform vesicular
protein transport to opposite cell poles, they qualify as
excellent models in order to study protein trafficking in
epithelial cells.
GFP-tagging and activity based probes as tools to study
protease trafficking in thyroid epithelial and carcinoma
cells
Previously, we have constructed a mammalian expres-
sion vector encoding cathepsin B-eGFP that proved sui-
table for trafficking studies of cathepsin B in the fully
differentiated and polarized rat thyroid epithelial cell
line FRT as well as in TSH-responsive FRTL-5 cells
[27]. This vector can also be used to analyze cathepsin
B transport in Chinese Hamster Ovary cells and in a
number of other cell types indicating that eGFP tagging
of cathepsin B does not grossly alter its trafficking in
mammalian cells. More recently, our original pCathB-
eGFP vector has been modified in the eGFP portion in
order to improve signal-to-noise ratios [49] and it was
sub-cloned into a modified plasmid for tissue-specific
expression under the control of the A33-antigen promo-
ter [50]. In these cases, the cathepsin B-encoding
sequence of the original vector was not altered.
In contrast, here we describe the construction of a
vector coding for an inactive mutant counter-part of
cathepsin B, in which the active site cysteine was substi-
tuted for an alanine. It was taken care to exchange
cysteine with alanine instead of the more likely
exchange of cysteine with serine (sulfhydryl side chain
would then be exchanged by hydroxyl group), because
we wanted to exclude the possibility of creating a serine
protease-like protein by site directed mutagenesis of the
cDNA coding for the cysteine peptidase cathepsin B. A
serine exchange could have meant to create a catalytic
dyad consisting of serine and histidine. Hence, our site-
directed mutagenesis and cloning strategy aimed at the
generation of an inactive enzyme with subtle changes in
the active site cleft. The goal was to modify the primary
structure of cathepsin B in such a way that the protein
would still fold properly and thus, would not induce an
unfolded protein response due to mis-folding and reten-
tion in the ER. In fact, these aims were achieved as is
obvious from the observation that cathepsin B-C29A-
eGFP chimeras proved fully transport-competent in the
normal thyroid epithelial cell line FRT (see Figure 6),
where it reached endo-lysosomes. In addition, the active
site mutant counterpart of cathepsin B was sorted into
endocytic compartments of the thyroid carcinoma cell
line HTh74 (see Figure 7).
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The cathepsin B-eGFP and cathepsin B-C29A-eGFP
chimeric proteins were not only expressed in normal
thyrocytes and in thyroid carcinoma cells, rather cathe-
psin trafficking was also investigated in combination
with the activity based probe GB117 [13,25] in order to
specify its sorting into transport vesicles. Hence, several
aspects of protease transport were addressed in this
study. (i) We analyzed whether active cysteine proteases
are directed to vesicles different from those that are
reached by inactive proteases. Thus, mature enzymes
would display specific sorting signals to direct them into
distinct sub-cellular compartments. (ii) As an alternative
explanation of re-routing of cathepsin B transport in
thyroid carcinoma cells, it was tested whether cathepsin
B can be transported differently when expressed in nor-
mal epithelial cells versus tumor-transformed cells.
Thus, assuming that sorting of proteases is governed by
the features of the different cell-types themselves.
We provide evidence for the notion that HTh74 cells,
although representing anaplastic thyroid carcinoma
cells, maintain transport competence and directed cathe-
psin B-eGFP in both versions, active and inactive, to
endo-lysosomes. In this respect, HTh74 cells clearly
resembled normal, non-transformed FRT cells that
transported both chimeric proteins to identical destina-
tions. However, the non-TSH receptor bearing anaplas-
tic thyroid carcinoma cell line HTh7 and the papillary
thyroid carcinoma cell line KTC-1 exhibited trafficking
defects. Here inactive cathepsin B was retained within
the ER and only the active cathepsin B-eGFP was trans-
ported further, i.e. up to the Golgi apparatus and to the
endo-lysosomes, respectively.
Conclusions
In this study, we showed that specific transport signals
within the sequence of cathepsin B are unlikely to exist
that would explain why thyroid carcinoma cells trans-
port the cysteine protease differently than normal thyr-
oid epithelial cells. Hence, future studies have to show
differences between benign and malignant or highly
invasive thyroid carcinoma cells. We propose that the
differences reside in expression of e.g. distinct members
of the Rab-protein family which are known to co-deter-
mine the directionality of protein transport in epithelial
and carcinoma cells of non-thyroid origin [51-53].
In summary, we conclude that protease trafficking
requires tight regulation in order to ensure proper phy-
siological functions. In a pathological context, mis-rou-
ted proteases can cleave in a non-regulated manner,
because they reach new locations and perform their
actions under conditions different from what is consid-
ered ‘normal’. Finally, re-routing of proteases in cancer
may well lead to altered proteolytic potencies in that
proteases will encounter a variety of substrates which
they would not have been able to interact with under
physiological conditions. Hence, the action of proteases
is decisive for normal and diseased functions of cells or
tissues in many respects. In turn, the understanding of
transport pathways of proteases in normal versus tumor
cells still provides clues for elucidating drug targets in
new therapeutic approaches.
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